Journal Watch · Journal of Controlled Release · 2026

An engineered probiotic co-expressing dual melanoma epitopes for therapeutic cancer vaccination.

This work presents a rationally designed bacterial vaccine platform for targeted cancer immunotherapy.

Wu B, Wang H, Yao C et al.Journal of Controlled Release3 min readPharma relevance 60/100

DOI: 10.1016/j.jconrel.2026.115124PMID: 42331227Study type: research study

TL;DR

This work presents a rationally designed bacterial vaccine platform for targeted cancer immunotherapy.

Key findings

  • It selectively accumulated in B16 melanoma tumors and elicited potent antigen-specific CD8<sup>+</sup> T cell responses, including tumor-specific cytotoxicity, IFN-γ production, and memory T cell expansion.
  • In a subcutaneous melanoma model, the vaccine suppressed tumor growth, prolonged survival, and remodeled the tumor microenvironment by increasing effector cell infiltration and reducing immunosuppressive regulatory T cells.
  • This work presents a rationally designed bacterial vaccine platform for targeted cancer immunotherapy.

What they did

The fusion protein, designed via AlphaFold3, incorporating an IgG Fc domain for stability and Listeriolysin O (LLO) for cytosolic delivery, with expression controlled by an L-arabinose-inducible promoter. The strain retained probiotic properties, was efficiently phagocytosed by antigen-presenting cells, and enhanced their maturation and antigen presentation.

Full abstract (original)

Background: Therapeutic cancer vaccines face challenges in tumor targeting, adjuvant dependency, and inefficient antigen cross-presentation. We engineered a probiotic vaccine using Escherichia coli Nissle 1917 co-expressing MHC-I epitopes from melanoma antigens Pmel17 and TYRP2.

What they did: The fusion protein, designed via AlphaFold3, incorporating an IgG Fc domain for stability and Listeriolysin O (LLO) for cytosolic delivery, with expression controlled by an L-arabinose-inducible promoter. The strain retained probiotic properties, was efficiently phagocytosed by antigen-presenting cells, and enhanced their maturation and antigen presentation.

Results & conclusions: It selectively accumulated in B16 melanoma tumors and elicited potent antigen-specific CD8<sup>+</sup> T cell responses, including tumor-specific cytotoxicity, IFN-γ production, and memory T cell expansion. In a subcutaneous melanoma model, the vaccine suppressed tumor growth, prolonged survival, and remodeled the tumor microenvironment by increasing effector cell infiltration and reducing immunosuppressive regulatory T cells. This work presents a rationally designed bacterial vaccine platform for targeted cancer immunotherapy.

Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.115124 · PubMed 42331227.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Controlled Release study find?

This work presents a rationally designed bacterial vaccine platform for targeted cancer immunotherapy.

What type of study is this?

It is a research study, published in Journal of Controlled Release in 2026. The fusion protein, designed via AlphaFold3, incorporating an IgG Fc domain for stability and Listeriolysin O (LLO) for cytosolic delivery, with expression controlled by an L-arabinose-inducible promoter.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jconrel.2026.115124. PubMed ID: 42331227. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wu B, Wang H, Yao C et al.. An engineered probiotic co-expressing dual melanoma epitopes for therapeutic cancer vaccination.. Journal of Controlled Release (2026). DOI: 10.1016/j.jconrel.2026.115124.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/an-engineered-probiotic-co-expressing-dual-melanoma-epitopes-for-therape-115124/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides